NBRV - Nabriva Therapeutics plc Looks to Continue to Trade Below its Annual-Low Share Price Today

Nabriva Therapeutics plc (NASDAQ:NBRV) traded today at a new 52-week low of $1.10. Approximately 12.1 million shares have changed hands today, as compared to an average 30-day volume of 1.8 million shares.

In the past 52 weeks, shares of Nabriva Therapeutics plc have traded between the current low of $1.10 and a high of $11.50 and is now at $1.11.

There is potential upside of 107.0% for shares of Nabriva Therapeutics plc based on a current price of $1.11 and an average consensus analyst price target of $2.31.

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer